{"groups":[{"description":"3mg/kg of nivolumab","id":"FG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"FG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"FG002","title":"Nivolumab + Lirilumab"},{"description":"ND regimen: Nivolumab (240 mg up to cycle 6, then 480 mg) + Daratumumab (16 mg/Kg)","id":"FG003","title":"Nivolumab + Daratumumab_Cohort A1"},{"description":"ND-PD regimen; Nivolumab + Daratumumab + Pomalidomide + Dexamethasone","id":"FG004","title":"Nivolumab + Daratumumab_Cohort A2"},{"description":"ND regimen: Nivolumab (240 mg cycle 1, then 480 mg) + Daratumumab (16 mg/Kg)","id":"FG005","title":"Nivolumab + Daratumumab_Cohort B1"},{"description":"D regimen: Daratumumab alone","id":"FG006","title":"Nivolumab + Daratumumab_Cohort B2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"52"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"31"},{"groupId":"FG006","numSubjects":"14"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}],"type":"AE unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"}],"type":"Request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"No longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}],"type":"Other Reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"}],"type":"Not Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"105"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"72"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"43"},{"groupId":"FG006","numSubjects":"22"}],"comment":"= Number of participants randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"40"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"7"},{"groupId":"FG006","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"104"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"72"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"36"},{"groupId":"FG006","numSubjects":"16"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"316 participants treated","recruitmentDetails":"For the phase 1 nivo monotherapy dose escalation included in this study, it was derived from CA209-003. It was concluded that 3mg/kg of nivolumab would be used for the dose expansion phase 2 of this study (CA209-039) based on the conclusions derived from CA209-003."}